SARS-CoV-2 variants of concern and the biological sex of patients affect the efficacy of molnupiravir, the first orally available drug approved for outpatient use against COVID-19, according to a new study led by researchers at Georgia State University.
A new universal flu vaccine protects against influenza B viruses, offering broad defense against different strains and improved immune protection, according to a new study by researchers in the Institute for Biomedical Sciences at Georgia State University.
A new universal flu vaccine constructed with key parts of the influenza virus offers broad cross protection against different strains and subtypes of influenza A viruses, according to a new study by researchers in the Institute for Biomedical Sciences.
A new oral treatment for ulcerative colitis that focuses on reducing inflammation in gut microbiota has been developed by researchers in the Institute for Biomedical Sciences at Georgia State University, according to a new study.
An oral antiviral drug that targets a key part of the respiratory syncytial virus (RSV) polymerase has been identified, a finding that could provide an effective treatment against RSV disease, according to researchers in the Center for Translational Antiviral Research at Georgia State University.
A nanoparticle vaccine that combines two proteins that induce immune responses against SARS-CoV-2, the virus that has caused the global pandemic, has the potential to be developed into broader and safe SARS-CoV-2 vaccines, according to researchers in the Institute for Biomedical Sciences at Georgia State University.
The new center at Emory and Georgia State is led and co-founded by researchers with a history of collaborating on successful antiviral drugs, including molnupiravir, which was one of the world’s first antiviral pills approved for use against SARS-CoV-2.
Georgia State researchers are teaming up with industry in new ways to help bring their innovative breakthroughs to the marketplace.
Drugs for inflammatory bowel disease are ineffective and have serious side effects. Professor Didier Merlin is developing a better treatment approach using nanotechnology.
Two biomedical science innovations from Georgia State University have been chosen to compete in STAT Madness 2022, a contest to select the top innovation or discovery in biomedical science from last year.
